Richard Scott Struthers - 11 Jul 2023 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
President & CEO, Director
Signature
/s/ Marc Wilson, as attorney-in-fact
Issuer symbol
CRNX
Transactions as of
11 Jul 2023
Transactions value $
-$1,010,317
Form type
4
Filing time
13 Jul 2023, 16:56:59 UTC
Previous filing
21 Jun 2023
Next filing
16 Aug 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Sale -$491K -24.4K -3.58% $20.14 656K 11 Jul 2023 By Family Trust 1 F1
transaction CRNX Common Stock Sale -$231K -11.5K -1.75% $20.17 645K 12 Jul 2023 By Family Trust 1 F2
transaction CRNX Common Stock Sale -$288K -14.2K -2.2% $20.35 631K 13 Jul 2023 By Family Trust 1 F3
holding CRNX Common Stock 126K 11 Jul 2023 Direct
holding CRNX Common Stock 1K 11 Jul 2023 By Spouse
holding CRNX Common Stock 90K 11 Jul 2023 By Family Trust 2
holding CRNX Common Stock 90K 11 Jul 2023 By Family Trust 3
holding CRNX Common Stock 90K 11 Jul 2023 By Family Trust 4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The common stock was sold by the reporting person in open market transactions on the transaction date, with a weighted average sales price of $20.14 per share. The range of sales prices on the transaction date was $20.10 to $20.25 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request
F2 The common stock was sold by the reporting person in open market transactions on the transaction date, with a weighted average sales price of $20.17 per share. The range of sales prices on the transaction date was $20.10 to $20.31 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
F3 The common stock was sold by the reporting person in open market transactions on the transaction date, with a weighted average sales price of $20.35 per share. The range of sales prices on the transaction date was $20.10 to $20.68 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.